搜索
http//．biother．orgChinJCancerBiotherOct．2016Vol．23No．5DOI10．3872/j．issn．1007-385X．2016．05．021··Ｒesearchprogressofthemoleculartargetedanti-tumordrugsintheeraofprecisionmedicine，(，110122)No．2015021。ProjectsupportedbytheTrainingProgramofInnovationandEntrepreneurshipforCollegeStudentsinLiaoningProvinceNo．20150211994－、E-mailxiongjiacmu@163．comWEIMinjiecorrespondingauthorE-mailmjwei@hotmail．com、。、、。。、。Ｒ730．5Ｒ979．1A1007-385X201605-0708-06、、。“”、、、。、、、。。1《2014》1〗。。、。。“3Ｒ”、、、、“”“”。、、、、。3、、123。、。。2“”。。20152“”precisionmedicineinitia-tive。。2016“”·807·．、。100。2FDA12。、3。。12015-2016FDA2015．02LenvatinibEisai、、2015．02PanobinostatNovartis2015．07SonidegibNovartis2015．11OmisertinibAstrazeneca3EGFＲ2015．11IxazomibMillenniumPharmaceuticals2016．01SpectrilaMedacGmbH2016．04NivolumabBristol-MyersSquibb2016．04AfatinibBoehringer-Ingelheim2016．04VenetoclaxAbbVieB-2BCL-22016．04AfatinibBoehringer-Ingelheim2016．04CabozantinibExelixis2016．04VenclextaAbbVie2016．05PalbociclibPfizer、EGFＲ、2016．05Nivolumab＆ipilimumabBMS2．1、。DNAMutThomolg1MTH1DNAMTH1。MTH1、ＲOSMTH14。Elf-1EtserythroblasttransformationspecificTEGFＲ-MEK1/2-EＲK、JNK1。5Elf-1、。。-1myeloidcellleukemia-1Mcl-16miＲ-193bMcl-1doxorubicinMDA-MB-231。STATJAK-STATSrc。STAT3EGFＲ、Src、Bcl-XL、Bcl-2、Mcl-1·907·201610235VEGF、Akt。STAT3、、。7STAT3、STAT3。KＲAS。8KＲAS54.5%BＲAF、PIK3CAHEＲ-2。。2、Gumeitini、MeifupairuiHydrochloride、SCC-31AvelasBiosciencesAVB-620X4PharmaceuticalsX4P-001ⅠCeruleanLYNPAＲZAⅠTＲACONTＲC105ⅠSellasLifeSciencesGroupGalinpepimut-SⅠBioInventTB-403ⅠCH-5132799ⅠEpitinibⅠBasileaPharmaceuticaBAL-3833ⅠTheliatinibⅠApitolisib、、ⅠIncyteINCB-39110ⅠNolatrexedDihydrochlorideⅡNantWorksAdenovirusⅡInnocrinSeviteronelⅡImmunomedicsSacituzumabGovitecanⅡVAXIMMVXM01ⅡBayerＲegorafenibⅢBoehringerIngelheimNintedanibⅢMustangBioMB-101Ⅲ2．2EGFＲ、BCＲ-Abl、ALK、VEGFＲ、B-ＲAF。·017·．96595EGFＲ、KＲASALK。2．2．1EGFＲEGFＲ-EGFＲ-TKIEGFＲgefitinib、erlotinib10。ＲNAMEG3EGFＲ11。12EGFＲ。2．2．2B-ＲAFB-ＲAF、、13B-ＲAF80%14。B-ＲAF1%～2%MEK/MAPK。15B-ＲAF。2．2．3anaplasticlymphomaki-naseALKcrizotinibALK57%13。10ALK16。17EGFＲALKpemetexedcarboplatin。AlectinibALK18。19ceritinibALK。2．2．4VEGFＲVEGFＲapatinibVEGFＲ-220。VEGFＲ-221。、VEG-FＲ。NSCLCVEG-FＲlinifanib22。2．2．5BCL-223BCL-2ABT-199AuroraAAKAMLN8237MYCN。BCL-2MCL-1Akt24。BCL-225。2．2．61(insulin-likegrowthfactor1receptor，IGF-1Ｒ)insulinreceptorsubstrateIＲSIGF-1ＲIGF26。27IGF-1ＲEGFＲ。FigitumumabIGF-1ＲIgG219IGF-1Ｒ。2．3、、、。28-30“”CAＲ-TT。1programmeddeath1PD-1PD-L1、T4cytotoxicTlymphocyte-associatedantigen-4CTLA-43132。———CTLA-4。33TNFβC35TNFβ。Yang34T———ACAT1、ACAT2。avasimibeACAT1CD8+TPD-1。2．4G35GPＲ160·117·201610235GPＲ160。ＲNAmiＲNAs、ln-cＲNAs、36。histonedeacetylaseHDAC13。isocitratedehydrogenaseIDH13。silybinCD4437。PYCＲ1PYCＲ1CＲISPＲ38。AGＲ2、CADM1。。39metform-inEGFＲ-TKITKI。3、、。、、。、。、。1．2014J．20142014216．2．J．201639011-18．DOI10．7501/j．issn．1674-6376．2016．01．001．3．5FDAJ．20162511-6．4．MTH1J．20153191199-1201．DOI10．3969/j．issn．1001-1978．2015．09．004．5．Elf-1J．2015345851-855．DOI10．3969/j．issn．1671-6264．2015．05．039．6．miＲ-193bJ．20153191584-1588．DOI10．3969/j．issn．1000-4718．2015．09．009．7．STAT3J．201524273074-3078．DOI10．3969/j．issn．1008-8849．2015．27．044．8NAMSKYUNSKOHJetal．BＲAFPIK3CAandHEＲ2oncogenicalterationsaccordingtoKＲASmutationstatusinad-vancedcolorectalcancerswithdistantmetastasisJ/OL．PLoSOne2016113e01518652016-07-25．http//．nc-bi．nlm．nih．gov/pmc/articles/PMC4798471/．DOI10．1371/journal．pone．0151865．9LEEBLEETLEESHetal．ClinicopathologiccharacteristicsofEGFＲKＲASandALKalterationsin6595lungcancersJ．Oncotarget201671723874-23884．DOI10．18632/oncotarget．8074．10．40J．201523202959-2961．DOI10．3969/j．issn．1672-4992．2015．20．23．11CHANGLWANGGJIATetal．Armoredlongnon-codingＲNAMEG3targetingEGFＲbasedonrecombinantMS2bacterio-phagevirus-likeparticlesagainsthepatocellularcarcinomaJ．Oncotarget201671723988-24004．DOI10．18632/onco-target．8115．12VANDPBBOONSTＲAMCSLOOTEＲMDetal．EGFＲtar-getednanobody-photosensitizerconjugatesforphotodynamictherapyinapre-clinicalmodelofheadandneckcancerJ/OL．JControlＲelease201622993-1052016-07-25．http//．science-direct．com/science/article/pii/S0168365916301481．DOI10．1016/j．jconrel．2016．03．014．13ATIQＲHEＲTZＲELDADSetal．SuppressionofB-ＲafV600EcancersbyMAPKhyper-activationJ．Oncotarget201671418694-18704．DOI10．18632/oncotarget．7909．14．J．20153910721-722．15ＲAFAELCGILBEＲTODCJIGNACIOGBetal．BＲAFmu-tationsinnon-smallcelllungcancerhasfinallyJanusopenedthedoorJ/OL．CritＲevOncolHematol201610132-392016-07-25．http//．croh-online．com/article/S1040-84281630036-1/abstract．DOI10．1016/j．critrevonc．2016．02．012．16ZITOMFMOＲABITOAGＲIDELLICetal．CrizotinibresponseinalaterelapseofALK-positivelungadenocarcinomaJ/OL．Ap-plImmunohistochemMolMorphol2016aheadofprint2016-07-25．http//journals．lww．com/appliedimmunohist/pages/articlev-·217·．iewer．aspxyear=9000＆issue=00000＆article=99105＆type=ab-stract．DOI10．1097/PAI．0000000000000328．17FANTSONGYJLIUXL．AdenocarcinomaofthelungwithconcomitantALKfusiongeneandEGFＲgenemutationacasere-portandliteraturereviewJ/OL．MolClinOncol201642203-2052016-07-25．http//．ncbi．nlm．nih．gov/pmc/ar-ticles/PMC4733966/．DOI10．3892/mco．2015．684．18TANAKAHTAIMAKMOＲIMOTOTetal．Dramaticre